The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis

<table>Forest plot of three included studies in DLBCL (F-PET, PFS). Pooled effect (HR) and heterogeneity test of an F-PET-positive scan on PFS in DLBCL patients (PET: positron emission tomography; PFS: progression-free survival; HR: hazard ratio; DLBCL: diffuse large B-cell lymphoma).</table>

BioMed Research International

fig4

Figure 4

Figure 4: The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis 

Figure 4 | The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis 